We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Caveat emptor

28 July 2016 By Sara Silver

Several industry mergers have fallen foul of tax rules and antitrust concerns. Yet Abbott’s $5.8 bln bid for Alere has so far resisted the diagnostics firm’s restatements, product recalls and subpoenas over Medicare billing and overseas sales. It’s a deal that needs to die.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)